Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Non Operating Income: 2021-2024

Historic Non Operating Income for ARS Pharmaceuticals (SPRY) over the last 4 years, with Dec 2024 value amounting to $11.4 million.

  • ARS Pharmaceuticals' Non Operating Income fell 22.10% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year decrease of 3.23%. This contributed to the annual value of $11.4 million for FY2024, which is 13.58% down from last year.
  • According to the latest figures from FY2024, ARS Pharmaceuticals' Non Operating Income is $11.4 million, which was down 13.58% from $13.2 million recorded in FY2023.
  • In the past 5 years, ARS Pharmaceuticals' Non Operating Income registered a high of $13.2 million during FY2023, and its lowest value of -$789,000 during FY2021.
  • For the 3-year period, ARS Pharmaceuticals' Non Operating Income averaged around $8.5 million, with its median value being $11.4 million (2024).
  • In the last 5 years, ARS Pharmaceuticals' Non Operating Income spiked by 1,250.62% in 2023 and then declined by 13.58% in 2024.
  • Over the past 4 years, ARS Pharmaceuticals' Non Operating Income (Yearly) stood at -$789,000 in 2021, then skyrocketed by 223.45% to $974,000 in 2022, then surged by 1,250.62% to $13.2 million in 2023, then fell by 13.58% to $11.4 million in 2024.